| Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension. | |
| | |
MedLine Citation:
|
PMID: 11230376 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The enzyme 11beta-hydroxysteroid dehydrogenase (11beta-HSD2) provides mineralocorticoid receptor specificity for aldosterone by metabolizing glucocorticoids to their receptor-inactive 11-dehydro derivatives. The present study investigated the effects of the aldosterone receptor antagonists spironolactone and eplerenone on endothelial function in liquorice-induced hypertension. Glycyrrhizic acid (GA), a recognized inhibitor of 11beta-HSD2, was supplemented to the drinking water (3 g/L) of Wistar-Kyoto rats over a period of 21 days. From days 8 to 21, spironolactone (5.8+/-0.6 mg. kg(-1). d(-1)), eplerenone (182+/-13 mg. kg(-1). d(-1)), or placebo was added to the chow (n=7 animals per group). Endothelium-dependent or -independent vascular function was assessed as the relaxation of preconstricted aortic rings to acetylcholine or sodium nitroprusside, respectively. In addition, aortic endothelial nitric oxide synthase (eNOS) protein content, nitrate tissue levels, and endothelin-1 (ET-1) protein levels were determined. GA increased systolic blood pressure from 142+/-8 to 185+/-9 mm Hg (P<0.01). In the GA group, endothelium-dependent relaxation was impaired compared with that in controls (73+/-6% versus 99+/-5%), whereas endothelium-independent relaxation remained unchanged. In the aortas of 11beta-HSD2-deficient rats, eNOS protein content and nitrate tissue levels decreased (1114+/-128 versus 518+/-77 microgram/g protein, P<0.05). In contrast, aortic ET-1 protein levels were enhanced by GA (308+/-38 versus 497+/-47 pg/mg tissue, P<0.05). Both spironolactone and eplerenone normalized blood pressure in animals on GA (142+/-9 and 143+/-9 mm Hg, respectively, versus 189+/-8 mm Hg in the placebo group; P<0.01), restored endothelium-dependent relaxation (96+/-3% and 97+/-3%, respectively, P<0.01 versus placebo), blunted the decrease in vascular eNOS protein content and nitrate tissue levels, and normalized vascular ET-1 levels. This is the first study to demonstrate that aldosterone receptor antagonism normalizes blood pressure, prevents upregulation of vascular ET-1, restores NO-mediated endothelial dysfunction, and thus, may advance as a novel and specific therapeutic approach in 11beta-HSD2-deficient hypertension. |
| | |
Authors:
|
T Quaschning; F Ruschitzka; S Shaw; T F Lüscher |
Related Documents
:
|
979066 - The effect of saralasin (1sar-8-ala-angiotensin ii) on blood pressure in patients with ... 12185466 - Liddle syndrome in a newborn infant. 9275376 - Relationship between some humoral factors and left ventricular hypertrophy in essential... 10852446 - Severity of hypertension in familial hyperaldosteronism type i: relationship to gender ... 21039346 - Spontaneous breathing during high-frequency oscillatory ventilation improves regional l... 15897926 - Relating drug-induced changes in carotid artery mechanics to cardiovagal and sympatheti... |
Publication Detail:
|
Type: Comparative Study; In Vitro; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Hypertension Volume: 37 ISSN: 1524-4563 ISO Abbreviation: Hypertension Publication Date: 2001 Feb |
Date Detail:
|
Created Date: 2001-03-20 Completed Date: 2001-04-26 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7906255 Medline TA: Hypertension Country: United States |
Other Details:
|
Languages: eng Pagination: 801-5 Citation Subset: IM |
Affiliation:
|
Institute of Physiology, Cardiovascular Research, University of Zürich, Zürich, Switzerland. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
11-beta-Hydroxysteroid Dehydrogenase Type 2 Animals Aorta / drug effects, physiology Blood Pressure / drug effects Body Weight / drug effects Endothelin-1 / analysis Endothelium, Vascular / drug effects*, physiology Enzyme Inhibitors / pharmacology Glycyrrhiza Glycyrrhizic Acid Heart Rate / drug effects Hydroxysteroid Dehydrogenases / antagonists & inhibitors, deficiency Hypertension / chemically induced, drug therapy*, metabolism Male Molecular Structure Nitrates / analysis Nitric Oxide / metabolism Nitric Oxide Synthase / analysis Nitric Oxide Synthase Type III Plants, Medicinal Rats Rats, Inbred WKY Receptors, Aldosterone / antagonists & inhibitors* Spironolactone / analogs & derivatives, chemistry, pharmacology, therapeutic use Vasodilation |
| Chemical | |
Reg. No./Substance:
|
0/Endothelin-1; 0/Enzyme Inhibitors; 0/Nitrates; 0/Receptors, Aldosterone; 0/eplerenone; 10102-43-9/Nitric Oxide; 1405-86-3/Glycyrrhizic Acid; 52-01-7/Spironolactone; EC 1.1.-/Hydroxysteroid Dehydrogenases; EC 1.1.1.146/11-beta-Hydroxysteroid Dehydrogenase Type 2; EC 1.14.13.39/Nitric Oxide Synthase; EC 1.14.13.39/Nitric Oxide Synthase Type III; EC 1.14.13.39/Nos3 protein, rat |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Antifibrotic effects of N-acetyl-seryl-aspartyl-Lysyl-proline on the heart and kidney in aldosterone...
Next Document: Educational instruction on a hospital information system for medical students during their surgical ...